Voyageur Pharmaceuticals Stock Net Income
| VYYRF Stock | USD 0.10 0.00 0.00% |
Fundamental analysis of Voyageur Pharmaceuticals allows traders to better anticipate movements in Voyageur Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Voyageur |
Voyageur Pharmaceuticals Company Net Income Analysis
Voyageur Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Voyageur Pharmaceuticals Net Income | (2.05 M) |
Most of Voyageur Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Voyageur Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Voyageur Pharmaceuticals reported net income of (2.05 Million). This is 100.6% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 100.36% higher than that of the company.
Voyageur Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Voyageur Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Voyageur Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Voyageur Pharmaceuticals by comparing valuation metrics of similar companies.Voyageur Pharmaceuticals is currently under evaluation in net income category among its peers.
Voyageur Fundamentals
| Return On Equity | -0.77 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | 5.74 M | |||
| Shares Outstanding | 132.7 M | |||
| Shares Owned By Insiders | 14.29 % | |||
| Price To Book | 4.11 X | |||
| EBITDA | (2.05 M) | |||
| Net Income | (2.05 M) | |||
| Cash And Equivalents | 247.78 K | |||
| Total Debt | 25.52 K | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 0.34 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (1.65 M) | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 10 | |||
| Beta | 0.9 | |||
| Market Capitalization | 9.93 M | |||
| Total Asset | 2.57 M | |||
| Net Asset | 2.57 M |
About Voyageur Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Voyageur Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Voyageur Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Voyageur Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Voyageur Pink Sheet
Voyageur Pharmaceuticals financial ratios help investors to determine whether Voyageur Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Voyageur with respect to the benefits of owning Voyageur Pharmaceuticals security.